tradingkey.logo
tradingkey.logo
Suchen

Aytu Biopharma Inc

AYTU
Zur Watchlist hinzufügen
2.160USD
+0.010+0.47%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
23.18MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Aytu Biopharma Inc Unternehmen

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.

Aytu Biopharma Inc Informationen

BörsenkürzelAYTU
Name des UnternehmensAytu Biopharma Inc
IPO-datumOct 20, 2017
CEODisbrow (Joshua R)
Anzahl der mitarbeiter82
WertpapierartOrdinary Share
GeschäftsjahresendeOct 20
Addresse7900 E. Union Avenue
StadtDENVER
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl80237
Telefon17204376580
Websitehttps://aytubio.com/
BörsenkürzelAYTU
IPO-datumOct 20, 2017
CEODisbrow (Joshua R)

Führungskräfte von Aytu Biopharma Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. John A. Donofrio, Jr.
Mr. John A. Donofrio, Jr.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Abhinav (Abi) Jian
Mr. Abhinav (Abi) Jian
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Aytu Biopharma Inc?

Die fünf größten Anteilseigner von Aytu Biopharma Inc sind: Mr. Jarrett T. (Josh) Disbrow

Wie viele Institutionen halten Anteile an Aytu Biopharma Inc (AYTU)?

Mit Stand vom 2026Q1 halten 69 Institutionen Anteile an Aytu Biopharma Inc, mit einem Gesamtmarktwert von etwa 3.87M, was 36.10% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -493525.00 gestiegen.

Was ist die größte Einnahmequelle von Aytu Biopharma Inc?

Am 2026Q1 erzielte das Geschäft mit ADHD portfolio für Aytu Biopharma Inc den höchsten Umsatz in Höhe von 13.22M, was 87.15% des Gesamtumsatzes entspricht.